RecruitingNCT04789915
Memantine added to aripiprazole for negative symptoms after first psychosis
About this title
Read the official source — NCT04789915Medication studyAges 18–45DenmarkSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 45 years.
- Listed locations
- Glostrup MunicipalitySee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 26, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 46
- Sponsor
- Bjorn H. Ebdrup
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Denmark
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT04789915
- Official title
Show the full official title
AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Glostrup Municipality
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bjorn H. Ebdrup.
Does this study involve medication?
Yes. The study involves medication, including Memantine and Placebo.
Who can participate?
Listed age limits: 18 years to 45 years.
Is this study still recruiting?
The registry lists this study as recruiting.
